On this page of StockholderLetter.com we present the latest annual shareholder letter from REVVITY, INC. — ticker symbol RVTY. Reading current and past RVTY letters to shareholders can bring important insights into the investment thesis.
From vision to reality: Solving global health challenges together. 2024 Annual Report
Revvity is supporting genome sequencing for newborn research through groundbreaking initiatives. 2
Dear Shareholders, As we reflect on our first full year as Revvity, I am pleased to share the progress we have made and the robust foundation we have built for a promising future. This year has been one of transformation, innovation, and triumph a testament to our team s dedication and our unwavering commitment to addressing the world s most pressing health challenges. Revvity s path has redefined innovation in life sciences and diagnostics establishing us as a category of one, uniquely positioned in high-growth markets and serving a broad customer base. Whether it s supporting advancements in cell and gene therapy or providing companion diagnostics for precision medicine, Revvity is at the forefront of scientific innovation that s transforming lives. Our progress this year underscores our ability to adapt, innovate, and lead in a rapidly changing industry. By aligning our focus with the evolving needs of our customers and the broader healthcare landscape, we positioned Revvity as a trusted partner in advancing global health. In an era where medicine is becoming increasingly personalized, we made significant strides in delivering high-value, tailored solutions that enable our customers to make a tangible difference in people s lives. In Life Sciences, we provide the know-how, reagents, instruments, software and services that enable preclinical R&D discovery and development. On the Diagnostics side, we are evolving from providing kits, assays, and instruments to contiguous workflows, whether to detect life threatening conditions in newborns or to diagnose a broad range of severe autoimmune disorders. In just the last year, our efforts resulted in several impactful advancements across Diagnostics and Life Sciences. For example, Revvity is supporting genome sequencing for newborn research through groundbreaking initiatives like Early Check, expanding the scope of rare genetic condition testing. In the important category of Alzheimer s disease, our in-vitro diagnostic EURORealTime APOE assay enables accurate genotyping of the APOE gene, critical to assessing a patient s risk for side effects prior to the start of an anti-amyloid (beta) therapy. And, as cancer research progresses with groundbreaking discoveries in targeted therapies and immunotherapies, our diverse portfolio of innovative products provides essential support to researchers. From genomics to precision medicine and beyond, we empower scientists to delve deeper into the complexities of cancer. The opportunities ahead of us are as vast as they are promising. We are committed to continuing our evolution as a company that not only supports our customers but also contributes to the wellbeing of society. Prahlad Singh, PhD President and CEO Revvity, Inc.
At Revvity, we are thoughtfully leveraging artificial intelligence both internally to enhance operational efficiency and externally through innovative solutions designed to address our customers future challenges. A prime example is Revvity Transcribe AI, a new solution specifically developed to streamline workflows and minimize the burden of manual data entry for our customers, enabling greater productivity and focus on critical tasks. None of these achievements would have been possible without Revvity s most important asset: our people. Across regions, businesses, and functions, our diverse and talented workforce is the driving force behind our success. The dedication to excellence, innovation, and collaboration of our employees defines who we are as a company. As we strive to tackle the world s most significant health challenges, we place great emphasis on discovering and supporting the next generation of innovative minds. To further this mission, we launched the Revvity Access STEM Scholarships, which aim to empower aspiring scientists. By endowing scholarships at universities worldwide, we are investing in the education of STEM students and reaffirming our commitment to the future of health and science. We remain dedicated to increasing awareness of our brand and the transformative impact we deliver to our customers, advancing efforts to bridge the gap between research and clinical practice, and embracing a strategic approach to AI as a core element of our enterprise enhancing efficiency and driving innovation across all areas. The opportunities ahead of us are as vast as they are promising. We are committed to continuing our evolution as a company that not only supports our customers but also contributes to the well-being of society. Together, we have the chance to create something truly extraordinary a legacy of innovation, collaboration, and positive impact that will endure for generations. On behalf of the leadership team at Revvity, thank you for your trust and partnership. It is your support that enables us to advance our purpose and achieve the remarkable milestones we celebrate today. I look forward to sharing more of our progress and achievements in the years to come. Regards, Prahlad
Corporate Governance Board of Directors Corporate Officers Prahlad Singh, PhD President and Chief Executive Officer Revvity, Inc. Prahlad Singh, PhD President and Chief Executive Officer Peter Barrett, PhD Partner Atlas Venture Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary Samuel R. Chapin Retired Executive Vice Chairman Bank of America Merrill Lynch Michael A. Klobuchar Chief Operating Officer Eikon Therapeutics, Inc. Michelle McMurry-Heath, MD, PhD Founder and Chief Executive Officer BioTechquity Clinical Max Krakowiak Senior Vice President and Chief Financial Officer Miriame Victor Senior Vice President, Chief Commercial Officer Alexis P. Michas Managing Partner Juniper Investment Company, LLC Tajinder Vohra Senior Vice President, Global Operations Sophie V. Vandebroek, PhD Former Vice President, Emerging Technology Partnerships IBM Corporation Anita Gonzales Vice President and Controller Michel Vounatsos Former Chief Executive Officer Biogen Inc. Frank Witney, PhD Former Chief Executive Officer Affymetrix, Inc. Pascale Witz Founder and President PWH Advisors
 • shareholder letter icon 3/12/2025 Letter Continued (Full PDF)
 • stockholder letter icon 3/8/2023 RVTY Stockholder Letter
 • stockholder letter icon 3/13/2024 RVTY Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon RVTY Benford's Law Stock Score = 87


RVTY Shareholder/Stockholder Letter Transcript:

From vision to reality:
Solving global health
challenges together.
2024 Annual Report

Revvity is supporting
genome sequencing for
newborn research through
groundbreaking initiatives.
2

Dear Shareholders,
As we reflect on our first full year as Revvity, I am pleased to share the progress we have
made and the robust foundation we have built for a promising future. This year has been
one of transformation, innovation, and triumph   a testament to our team   s dedication and
our unwavering commitment to addressing the world   s most pressing health challenges.
Revvity   s path has redefined innovation in life sciences and diagnostics establishing us as a
category of one, uniquely positioned in high-growth markets and serving a broad customer
base. Whether it   s supporting advancements in cell and gene therapy or providing
companion diagnostics for precision medicine, Revvity is at the forefront of scientific
innovation that   s transforming lives.
Our progress this year underscores our ability to adapt, innovate,
and lead in a rapidly changing industry. By aligning our focus with
the evolving needs of our customers and the broader healthcare
landscape, we positioned Revvity as a trusted partner in advancing
global health. In an era where medicine is becoming increasingly
personalized, we made significant strides in delivering high-value,
tailored solutions that enable our customers to make a tangible
difference in people   s lives.
In Life Sciences, we provide the know-how, reagents, instruments,
software and services that enable preclinical R&D discovery
and development. On the Diagnostics side, we are evolving from
providing kits, assays, and instruments to contiguous workflows,
whether to detect life threatening conditions in newborns or to
diagnose a broad range of severe autoimmune disorders.
In just the last year, our efforts resulted in several impactful
advancements across Diagnostics and Life Sciences. For example,
Revvity is supporting genome sequencing for newborn research
through groundbreaking initiatives like Early Check, expanding the
scope of rare genetic condition testing. In the important category
of Alzheimer   s disease, our in-vitro diagnostic EURORealTime   
APOE assay enables accurate genotyping of the APOE gene,
critical to assessing a patient   s risk for side effects prior to the
start of an anti-amyloid (beta) therapy. And, as cancer research
progresses with groundbreaking discoveries in targeted therapies
and immunotherapies, our diverse portfolio of innovative products
provides essential support to researchers. From genomics to
precision medicine and beyond, we empower scientists to delve
deeper into the complexities of cancer.
   The opportunities ahead of
us are as vast as they are
promising. We are committed
to continuing our evolution
as a company that not only
supports our customers but
also contributes to the wellbeing of society.   
Prahlad Singh, PhD
President and CEO
Revvity, Inc.

At Revvity, we are thoughtfully leveraging artificial intelligence both internally to enhance
operational efficiency and externally through innovative solutions designed to address our
customers    future challenges. A prime example is Revvity Transcribe AI, a new solution
specifically developed to streamline workflows and minimize the burden of manual data entry for
our customers, enabling greater productivity and focus on critical tasks.
None of these achievements would have
been possible without Revvity   s most
important asset: our people. Across regions,
businesses, and functions, our diverse and
talented workforce is the driving force behind
our success. The dedication to excellence,
innovation, and collaboration of our
employees defines who we are as a company.
As we strive to tackle the world   s most significant health challenges, we place great emphasis
on discovering and supporting the next generation of innovative minds. To further this mission,
we launched the Revvity Access STEM Scholarships, which aim to empower aspiring scientists.
By endowing scholarships at universities worldwide, we are investing in the education of STEM
students and reaffirming our commitment to the future of health and science.
We remain dedicated to increasing awareness of our brand and the transformative impact we
deliver to our customers, advancing efforts to bridge the gap between research and clinical
practice, and embracing a strategic approach to AI as a core element of our enterprise   
enhancing efficiency and driving innovation across all areas.
The opportunities ahead of us are as vast as they are promising. We are committed to continuing
our evolution as a company that not only supports our customers but also contributes to the
well-being of society. Together, we have the chance to create something truly extraordinary   a
legacy of innovation, collaboration, and positive impact that will endure for generations.
On behalf of the leadership team at Revvity,
thank you for your trust and partnership. It is
your support that enables us to advance our
purpose and achieve the remarkable milestones
we celebrate today. I look forward to sharing
more of our progress and achievements in the
years to come.
Regards,
Prahlad

Corporate Governance
Board of Directors
Corporate Officers
Prahlad Singh, PhD
President and Chief Executive Officer
Revvity, Inc.
Prahlad Singh, PhD
President and Chief Executive Officer
Peter Barrett, PhD
Partner
Atlas Venture
Joel S. Goldberg
Senior Vice President,
Administration, General
Counsel and Secretary
Samuel R. Chapin
Retired Executive Vice Chairman
Bank of America Merrill Lynch
Michael A. Klobuchar
Chief Operating Officer
Eikon Therapeutics, Inc.
Michelle McMurry-Heath, MD, PhD
Founder and Chief Executive Officer
BioTechquity Clinical
Max Krakowiak
Senior Vice President and
Chief Financial Officer
Miriame Victor
Senior Vice President,
Chief Commercial Officer
Alexis P. Michas
Managing Partner
Juniper Investment Company, LLC
Tajinder Vohra
Senior Vice President, Global Operations
Sophie V. Vandebroek, PhD
Former Vice President,
Emerging Technology Partnerships
IBM Corporation
Anita Gonzales
Vice President and Controller
Michel Vounatsos
Former Chief Executive Officer
Biogen Inc.
Frank Witney, PhD
Former Chief Executive Officer
Affymetrix, Inc.
Pascale Witz
Founder and President
PWH Advisors



shareholder letter icon 3/12/2025 Letter Continued (Full PDF)
 

RVTY Stockholder/Shareholder Letter (REVVITY, INC.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.